Skip to main content
. 2014 Aug 4;29(5):470–482. doi: 10.1002/hup.2424

Table 4.

Treatment-emergent adverse events (TEAEs) with an incidence of ≥5% in either treatment group in the 12-week treatment period (all-patients-treated set)

Preferred term Vortioxetine 10–20 mg, n (%) (n = 253) Agomelatine 25–50 mg, n (%) (n = 242)
Patients with TEAEs 137 (54.2) 127 (52.5)
 Nausea 41 (16.2) 22 (9.1)
 Headache 26 (10.3) 32 (13.2)
 Dizziness 18 (7.1) 28 (11.6)
 Somnolence 10 (4.0) 19 (7.9)